psoriasis. Psoriasis vulgaris
Conditions
Interventions
Intervention 1: Intervention: Atorvastatin Tablet 40 mg, one tablet /day. Intervention 2: Placebo tablet, one tablet per day.
Treatment - Drugs
Placebo
Intervention: Atorvastatin Tablet 40 mg, one tablet /day
Placebo tablet, one tablet per day
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- Diagnosis of acute or chronic plaque-type psoriasis. 2- Patients with moderate disease severity (BSA involvement of at least 10% and PASI score between 12-21%). 3- Male or female patients with age range of 16-60 years. 4- Patients who have not been treated with atorvastatin or other statins within one month prior to study participation. Exclusion criteria: 1- Patients with types of psoriasis other than plaque. 2- Patients who are candidate to receive atorvastatin or other statins due to other medical conditions at trial entry and any time during the trial. 3- Pregnancy 4- Lactation 5- Having contraindications to atorvastatin. 6- Patients' refusal to participate. 7- Patients who are candidate to receive systemic therapy or phototherapy for psoriasis at the time of study entry or any time during the study. 8- Patients who are candidate to receive topical therapies other than allowed at the time of study entry or any time during the study. 9- Patients with psoriatic arthritis. 10- Systemic therapy and phototherapy for psoriasis within 30 days prior to study participation. 11- Topical therapy for psoriasis (other than allowed) within 2 weeks of study participation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis disease severity. Timepoint: Baseline, every 4 weeks, end of week 12. Method of measurement: PASI score (standard methods).;Body surface area (BSA). Timepoint: Baseline, every 4 weeks, end of week 12. Method of measurement: Standard method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. T. Faghihi
Tehran University of Medical Sciences
Outcome results
None listed